Premium
Evaluation of the 2‐(1‐Hexyloxyethyl)‐2‐devinyl pyropheophorbide (HPPH) mediated photodynamic therapy by macroscopic singlet oxygen modeling
Author(s) -
Penjweini Rozhin,
Kim Michele M.,
Liu Baochang,
Zhu Timothy C.
Publication year - 2016
Publication title -
journal of biophotonics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.877
H-Index - 66
eISSN - 1864-0648
pISSN - 1864-063X
DOI - 10.1002/jbio.201600121
Subject(s) - photodynamic therapy , singlet oxygen , photobleaching , photosensitizer , fluence , nuclear medicine , oxygen , fibrosarcoma , chemistry , radiation therapy , fluorescence , photochemistry , medicine , optics , laser , pathology , surgery , physics , organic chemistry
Photodynamic therapy (PDT) is known as a non‐invasive treatment modality that is based on photochemical reactions between oxygen, photosensitizer, and a special wavelength of light. However, a dosimetric predictor for PDT outcome is still elusive because current dosimetric quantities do not account for the differences in the PDT oxygen consumption rate for different fluence rates. In this study, we evaluate several dose metrics, total fluence, photobleaching ratio, PDT dose, and mean reacted singlet oxygen (mean [ 1 O 2 ] rx ) for predicting the PDT outcome and a clinically relevant tumor re‐growth endpoint. For this reason, radiation‐induced fibrosarcoma (RIF) mice tumors are treated with 2‐(1‐Hexyloxyethyl)‐2‐devinyl pyropheophorbide (HPPH) and different in‐air fluences (30 J/cm 2 , 50 J/cm 2 , 135 J/cm 2 , 250 J/cm 2 , and 350 J/cm 2 ) and in‐air fluence rates (20, 50, 75, 150 mW/cm 2 ). Explicit measurements of HPPH and oxygen concentration as well as tissue optical properties are performed pre‐ and post‐treatment. Then, this information is incorporated into a macroscopic model to calculate the photobleaching, PDT dose, and mean [ 1 O 2 ] rx . Changes in tumor volume are tracked following the treatment and compared with the dose metrics. The correlation demonstrates that mean [ 1 O 2 ] rx serves as a better dosimetric quantity for predicting treatment outcome and a clinically relevant tumor re‐growth endpoint.